IPHA — Innate Pharma S.A.

Innate Pharma (IPHA) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue and Income: Total revenue and other income for 2025 amounted to EUR 9 million, including EUR 2.8 million from licensing and collaboration agreements and EUR 6.2 million in governmental funding.
• Operating Expenses: Total operating expenses were EUR 63 million, with R&D expenses at EUR 43.6 million (down 16% year-over-year) and G&A expenses at EUR 19.4 million (stable year-on-year).
• Cash Position: Ended 2025 with EUR 44.8 million in cash, providing funding visibility until the end of Q3 2026.

2. Strategic Updates and Business Highlights

• Focus on Key Assets: Innate Pharma is prioritizing three main assets: lacutamab, IPH4502, and monalizumab, aiming to streamline operations and enhance decision-making.
• Lacutamab: Received FDA clearance for the TELLOMAK-3 Phase III trial in cutaneous T-cell lymphoma (CTCL), expected to initiate in H2 2026. The company is exploring financing options for this study.
• IPH4502: A novel Nectin-4 antibody-drug conjugate (ADC) showing early signs of antitumor activity in heavily pretreated patients. The Phase I trial is ongoing, with promising preclinical data suggesting it may address unmet needs in urothelial cancer.
• Monalizumab: The PACIFIC-9 Phase III trial in non-small cell lung cancer has completed enrollment, with data expected in H2 2026.

3. Forward Guidance and Outlook

• Clinical Milestones: Multiple catalysts expected in the near to medium term, particularly with lacutamab and IPH4502. The company aims to leverage partnerships and financing structures to support late-stage development.
• Commercial Strategy: A focused approach for lacutamab in CTCL, targeting a concentrated treatment landscape with a potential initial market opportunity of up to EUR 150 million in Sezary Syndrome, expanding to over EUR 500 million when including Mycosis Fungoides.

4. Bad News, Challenges, or Points of Concern

• Restructuring Impact: The company has implemented a redundancy plan, which may affect morale and operational capacity.
• Revenue Decline: Collaboration revenue from the monalizumab program has dropped significantly, reflecting the transition of responsibilities to AstraZeneca.
• Competitive Landscape: The ADC market is evolving, and while IPH4502 is positioned well, there are ongoing competitive pressures that could impact its market entry and adoption.

5. Notable Q&A Insights

• Partnership Discussions: Ongoing discussions regarding potential partnerships for lacutamab are focused on maximizing shareholder value and ensuring timely market entry.
• Antitumor Activity: Preliminary data from IPH4502 shows activity in multiple tumor types, with ongoing efforts to present findings at medical conferences as data matures.
• Sales Infrastructure: If Innate Pharma decides to commercialize lacutamab independently, a small sales team of approximately 20 people is anticipated, given the concentrated treatment centers for CTCL.

Overall, Innate Pharma is navigating a pivotal period with a focused strategy on its key assets, while also addressing challenges related to restructuring and revenue generation. The upcoming clinical milestones and potential partnerships are critical for the company's growth trajectory.